Zhejiang Starry Pharmaceutical Co (SHSE:603520) Quality Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603520 Zhejiang Starry Pharmaceutical Co Ltd SHSE:603520
76 GF Score
Price ¥8.56
GF Value ¥9.24
Valuation Fairly Valued
! 10 Warning Signs
View Full Analysis

What is Zhejiang Starry Pharmaceutical Co Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Zhejiang Starry Pharmaceutical Co Quality Rank Related Terms

SHSE:603520
76GF Score
Zhejiang Starry Pharmaceutical Co Ltd SHSE:603520
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Zhejiang Starry Pharmaceutical Co (SHSE:603520) Overvalued in 2026?

Based on GuruFocus' analysis, Zhejiang Starry Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥8.56 is trading 7.4% below its estimated GF Value™ of ¥9.24. GuruFocus considers Zhejiang Starry Pharmaceutical Co to be Fairly Valued.

Key valuation signals for SHSE:603520:

  • Quality Rank:
  • GF Value™: ¥9.24 vs. price of ¥8.56 (7.4% below fair value)
  • GF Score™: 76/100 with 10 warning signs

No single metric tells the full story. See the SHSE:603520 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Zhejiang Starry Pharmaceutical Co Business Description

Address No.1 Sitali Avenue, Modern Industrial Gathering District, Zhejiang Province, Xianju County, Taizhou City, CHN, 317306
Zhejiang Starry Pharmaceutical Co Ltd is engaged in R&D, manufacture and marketing of active ingredient and intermediate X-CT non-ionic contrast agent series and Fluoroquinolones series.
76GF Score

Get the complete analysis for SHSE:603520

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥8.56
Price
¥9.24
GF Value